Hough, David

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 904

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 795

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 676

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 606

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 481

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 418

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)

Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 376

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 308

Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia

Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research

Schizophrenia research and treatmentStatistical Methods in Clinical Trials

Cited by 110

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

Ravenstijn, P., Remmerie, B., Savitz, A., Samtani, M. N., Nuamah, I., Chang, C., De Meulder, M., Hough, D., & Gopal, S. (2016) · The Journal of Clinical Pharmacology

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 86

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

Coppola, D., Liu, Y., Gopal, S., Remmerie, B., Samtani, M. N., Hough, D. W., Nuamah, I., Sulaiman, A., & Pandina, G. (2012) · BMC Psychiatry

Schizophrenia research and treatmentPharmacogenetics and Drug Metabolism

Cited by 61

A single‐dose, open‐label, parallel, randomized, dose‐proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

Cleton, A., Rossenu, S., Crauwels, H., Berwaerts, J., Hough, D., Gopal, S., Eerdekens, M., Vandebosch, A., Remmerie, B., De Meulder, M., et al. (2014) · The Journal of Clinical Pharmacology

Schizophrenia research and treatmentIntramuscular injections and effects

Cited by 48

Approval of esketamine for treatment-resistant depression

Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 46

Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia

Rossenu, S., Cleton, A., Hough, D., Crauwels, H., Vandebosch, A., Berwaerts, J., Eerdekens, M., Herben, V., De Meulder, M., Remmerie, B., et al. (2015) · Clinical Pharmacology in Drug Development

Schizophrenia research and treatmentIntramuscular injections and effects

Cited by 26

Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study

Wajs, E., Leah, A., Morrison, R., Daly, E., Lane, R., Lim, P., Holder, R., Sanacora, G., Young, A. H., Kasper, S., et al. (2019) · European Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 19

S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression

Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Foster, K., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2018) · Biological Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 17

Comment on a Word to the Wise About Intranasal Esketamine

Drevets, W. C., Singh, J. B., Hough, D., Daly, E. J., Popova, V., & Manji, H. (2019) · American Journal of Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 12

Randomized, Double-Blind Study of Fixed-Dose Intranasal Esketamine Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression

Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · Journal of Affective Disorders

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 5

Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression

Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · European Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 2